NCT05387967View on ClinicalTrials.gov

Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction

PHASE4CompletedINTERVENTIONAL

Enrollment

121

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

June 30, 2021

Study Completion Date

September 30, 2021

Conditions

Heart Failure, Systolic

Interventions

DRUG

Sacubitril/valsartan

All the recruited patients were prescribed Sacubitril/Valsartan at a starting dose of 50 (24/26) mg BID which was up-titrated, over the period of initial 6 weeks, to the maximum tolerated dose up to 200 (97/103) mg BID and further followed for a total of 12 weeks.

Trial Locations (1)

75510

National Institute of Cardiovascular Diseases, Karachi

All Listed Sponsors

lead

National Institute of Cardiovascular Diseases, Pakistan

OTHER

NCT05387967 - Safety and Tolerability of Sacubitril/Valsartan in Heart Failure Patient With Reduced Ejection Fraction | Biotech Hunter | Biotech Hunter